Lixte Biotechnology Holdings Inc (LIXT)
2.338
+0.01
(+0.35%)
USD |
NASDAQ |
May 31, 16:00
2.32
-0.02
(-0.77%)
After-Hours: 20:00
Lixte Biotechnology Holdings Research and Development Expense (TTM): 0.8281M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.8281M |
| December 31, 2023 | 0.8981M |
| September 30, 2023 | 1.203M |
| June 30, 2023 | 1.343M |
| March 31, 2023 | 1.080M |
| December 31, 2022 | 1.349M |
| September 30, 2022 | 1.699M |
| June 30, 2022 | 1.654M |
| March 31, 2022 | 1.752M |
| December 31, 2021 | 1.737M |
| September 30, 2021 | 1.145M |
| June 30, 2021 | 1.717M |
| March 31, 2021 | 1.572M |
| December 31, 2020 | 1.224M |
| September 30, 2020 | 1.134M |
| June 30, 2020 | 0.9051M |
| March 31, 2020 | 0.8673M |
| December 31, 2019 | 0.8209M |
| September 30, 2019 | 0.6695M |
| June 30, 2019 | 0.1023M |
| March 31, 2019 | 0.0633M |
| December 31, 2018 | 0.0407M |
| September 30, 2018 | 0.174M |
| June 30, 2018 | 0.3763M |
| March 31, 2018 | 0.3497M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.4673M |
| September 30, 2017 | 0.5142M |
| June 30, 2017 | 0.6444M |
| March 31, 2017 | 0.9468M |
| December 31, 2016 | 1.068M |
| September 30, 2016 | 1.592M |
| June 30, 2016 | 1.881M |
| March 31, 2016 | 1.851M |
| December 31, 2015 | 2.092M |
| September 30, 2015 | 1.727M |
| June 30, 2015 | 1.412M |
| March 31, 2015 | 1.461M |
| December 31, 2014 | 1.118M |
| September 30, 2014 | 1.052M |
| June 30, 2014 | 0.9633M |
| March 31, 2014 | 0.8764M |
| December 31, 2013 | 0.8799M |
| September 30, 2013 | 0.7627M |
| June 30, 2013 | 0.9364M |
| March 31, 2013 | 0.9049M |
| December 31, 2012 | 1.012M |
| September 30, 2012 | 1.369M |
| June 30, 2012 | 1.34M |
| March 31, 2012 | 1.347M |
| December 31, 2011 | 1.335M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.1023M
Minimum
Jun 2019
1.752M
Maximum
Mar 2022
1.185M
Average
1.174M
Median
Research and Development Expense (TTM) Benchmarks
| iBio Inc | 6.401M |
| PAVmed Inc | 12.17M |
| PDS Biotechnology Corp | 28.62M |
| Moleculin Biotech Inc | 18.05M |
| Syros Pharmaceuticals Inc | 104.05M |